After the change in leadership at GlaxoSmithKline plc Sponsored ADR (GSK.US), Goldman Sachs Group, Inc. reiterated a "neutral" rating.

After GlaxoSmithKline plc Sponsored ADR (GSK.US) announced the replacement of its CEO, Goldman Sachs Group, Inc. issued a research report, reiterating a "neutral" rating on GlaxoSmithKline plc Sponsored ADR with a target price of $41. On September 29th, GlaxoSmithKline plc Sponsored ADR announced that Luke Miels has been appointed as the CEO designate, and will officially assume the role of CEO on January 1, 2026, replacing current CEO Emma Walmsley. Miels joined GlaxoSmithKline plc Sponsored ADR in 2017 as Chief Commercial Officer, and has played a key role in building the company's specialist pharmaceutical portfolio, particularly in oncology and respiratory areas. Prior to joining GlaxoSmithKline plc Sponsored ADR, Miels held several senior positions at companies like Astrazeneca PLC Sponsored ADR, Roche, and Sanofi. According to GlaxoSmithKline plc Sponsored ADR, "both internal and external candidates were considered for the role. Walmsley will step down from the board on December 31, 2025, but will remain with the company until September 30, 2026, to ensure a smooth transition process." Goldman Sachs Group, Inc. believes that the new CEO's primary communication will focus on assuring the market of GlaxoSmithKline plc Sponsored ADR's strategy to achieve its long-term goals, particularly the sales guidance to exceed 40 billion by 2031, as reiterated in the press release. Additionally, Goldman Sachs Group, Inc. expects investors to focus on details of how the new CEO can enhance the company's innovation capabilities. Goldman Sachs Group, Inc. considers this crucial for driving a meaningful revaluation of the stock, as it has been trading at lower levels compared to its industry peers.